Modified VEGF oligonucleotides for treatment of skin disorders
AssigneeHybridon, Inc.
InventorsAdrienne P. Smyth, Gregory S. Robinson
Life of this patent
Estimating the term…
Abstract
Disclosed are oligonucleotides complementary to VEGF-specific nucleic acid useful in reducing the expression of VEGF. Also disclosed are pharmaceutical formulations containing such oligonucleotides useful for treating various disorders associated with neovascularization and angiogenesis, and methods for treating psoriasis.
Claims8
A method of inhibiting vascular endothelial growth factor expression in human epidermal keratinocyte cells, comprising the step of locally administering to said cells a therapeutically effective amount of a synthetic oligonucleotide complementary to a human vascular endothelial growth factor target nucleic acid, whereby expression of said vascular endothelial growth factor is inhibited, the oligonucleotide having a nucleotide sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7, SEQ ID NO:8, SEQ ID NO:9, SEQ ID NO:10, SEQ ID NO:11, SEQ ID NO:12, SEQ ID NO:13, SEQ ID NO:14, SEQ ID NO:15, and SEQ ID NO:16.
Dependencies are inferred from the claim text.